Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allon Therapeutics
ClinicalTrials.gov Identifier:
NCT01110720
First received: April 23, 2010
Last updated: January 15, 2013
Last verified: January 2013